EyePoint, Inc. (Nasdaq: EYPT) announced it will report fourth quarter and full-year 2025 financial results during a conference call scheduled for March 4, 2026. The clinical-stage biopharmaceutical company will provide investors with a comprehensive review of its operational and financial performance, alongside updates on its development pipeline.
The company's lead asset, DURAVYU™, continues to progress through late-stage clinical evaluation for retinal diseases. EyePoint expects to initiate dosing in Phase 3 diabetic macular edema trials during the first quarter of 2026, while Phase 3 pivotal studies evaluating DURAVYU™ for wet age-related macular degeneration are positioned to generate topline data beginning in mid-2026. These milestones represent critical inflection points for the company's clinical program.
The March earnings call will provide an opportunity for management to discuss financial positioning, regulatory progress, and strategy as the company approaches multiple trial readouts. Investors and stakeholders will be able to assess EyePoint's operational execution and cash runway alongside the advancement of its sustained-delivery therapeutic platform.